



ASX Announcement

28 January 2020

Creso Pharma's exceeds milestone of 2.5 million cannaQIX® lozenges sold globally

Highlights

- Creso Pharma's flagship product line cannaQIX® recently surpassed the significant milestone of 2.5 million lozenges sold, globally, which represents over 100,000 packs sold.
- Launched in April 2018, cannaQIX® helps users managing stress and pain as well as improving sleep
- Creso Pharma produces and markets cannaQIX® in collaboration with several partners in Europe and Oceania

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to announce that its flagship cannaQIX® line exceeded the significant milestone of 2.5 million lozenges sold, globally, which represents over 100,000 packs sold since its launch in April 2018. Revenue from the sale of cannaQIX® lozenges in 2019 exceeded AUD \$1 million (unaudited).

The cannaQIX® hemp oil derived food supplement is currently available in Switzerland, UK, Australia, Brazil and New Zealand.

Creso Pharma developed cannaQIX® 10 to help manage stress and cannaQIX® 25 and 50 to help manage chronic pain. The initial target markets for these products were Switzerland, UK, Australia, New Zealand and Brazil.

The Company produces the cannaQIX® range of products in Switzerland and is commercialising them in collaboration with several partners in Europe, Oceania and Latin America.

The products are being distributed through pharmacies and drug stores in Europe as well as through doctors and clinics in Oceania and Latin America.

Dr. Miri Halperin Wernli, Co-Founder and CEO said: "We are proud that cannaQIX® has reached this milestone. The cannaQIX® line is Creso Pharma's hemp oil/vitamins & minerals based food supplement, oral cosmetic and medical cannabis, which has been developed with a unique proprietary buccal delivery system.




The products help manage stress and pain, and support better sleep. We are looking forward to upcoming launches together with our new partners in additional countries and continents such as South Africa and Latin America in 2020."

The products available in each country are shown below:

Switzerland



The UK




The Netherlands



Germany



New Zealand



Brazil



Australia





Jorge Wernli, Commercial Director said: “Creso Pharma’s cannaQIX® hemp oil-derived products are unique, all Swiss-made, and produced in GMP facilities complying with local regulatory requirements. Creso Pharma has developed an attractive product portfolio responding to customer needs and complying with regulations. With our technological capabilities and international scientific and commercial partnerships, we are well-positioned to continue growing our portfolio of commercialised animal and human health products.”

Ends.

Authority and Contact Details

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

EverBlu Capital
E: info@everblucapital.com
P: +61 2 8249 0000

Media Enquiries

Julia Maguire | The Capital Network
E: julia@thecapitalnetwork.com.au
P: +61 419 815 386

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

**Forward Looking statements**

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations.

The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.